Literature DB >> 7827297

Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line.

K Okada1, Y Shimizu, S Nambu, K Higuchi, A Watanabe.   

Abstract

The tumour cells of a human cholangiocarcinoma cell line, HuCC-T1, were found to express mRNA of interleukin-6 (IL-6) and to secrete a large amount of biologically active IL-6 in the culture medium at the concentration of 22.6 ng/mL. Interleukin-6 was demonstrated in the cytoplasm of the cells by immunohistochemical staining. Furthermore, these cells showed the presence of receptors for IL-6 on the surface, and DNA synthesis of the cells was stimulated by the exogenous addition of recombinant human IL-6 into the culture medium. The cell growth was significantly inhibited in the presence of anti-human IL-6 antibody in the culture medium. These findings indicate that IL-6 is one of the autocrine growth factors of this cell line in vitro.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827297     DOI: 10.1111/j.1440-1746.1994.tb01275.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  28 in total

1.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

Review 2.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

3.  Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma.

Authors:  Masataka Okuno; Tomoki Ebata; Yukihiro Yokoyama; Tsuyoshi Igami; Gen Sugawara; Takashi Mizuno; Junpei Yamaguchi; Masato Nagino
Journal:  J Gastroenterol       Date:  2015-07-18       Impact factor: 7.527

4.  Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.

Authors:  Hajime Isomoto; Justin L Mott; Shogo Kobayashi; Nathan W Werneburg; Steve F Bronk; Serge Haan; Gregory J Gores
Journal:  Gastroenterology       Date:  2006-11-07       Impact factor: 22.682

5.  Molecular mechanisms of cholangiocarcinoma.

Authors:  Giammarco Fava
Journal:  World J Gastrointest Pathophysiol       Date:  2010-04-15

6.  Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes.

Authors:  Yoko Yamagiwa; Fanyin Meng; Tushar Patel
Journal:  Life Sci       Date:  2005-12-05       Impact factor: 5.037

Review 7.  Obesity and cholangiocarcinoma.

Authors:  Mansour A Parsi
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

8.  Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth.

Authors:  Tetsuya Shimizu; Shigeki Yokomuro; Yoshiaki Mizuguchi; Yutaka Kawahigashi; Yasuo Arima; Nobuhiko Taniai; Yasuhiro Mamada; Hiroshi Yoshida; Koho Akimaru; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

Review 9.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

10.  High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6.

Authors:  B Xu; U Broome; B-G Ericzon; S Sumitran-Holgersson
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.